1. Detection of AFP content in adult blood: AFP content in 60%~70%  patients with primary liver cancer increases, in addition, AFP content  in patients with testicular cancer, ovarian tumor, malignant teratoma,  pancreatic cancer, gastric cancer, intestinal cancer, lung cancer and  other patients will also increase. 

2. Detection of AFP levels in childhood blood: AFP levels increase in  liver cancer, hepatoblastoma, gonadal teratoblastoma, hepatitis, and  other conditions. 

3. Patients with benign liver diseases such as acute and chronic  hepatitis and cirrhosis also have varying degrees of elevated blood  AFP levels, but most of them are below 1000ng/mL, which is related to  the degree of liver cell necrosis and regeneration. 

4. Generally, the increase in AFP content in benign liver disease is  transient and usually lasts for 2-3 weeks. Malignant tumors, on the  other hand, continue to rise. Therefore, dynamic observation of serum  AFP levels can distinguish between benign and malignant liver  diseases, as well as early diagnosis of liver cancer. 

5. Physiologically, AFP is secreted by newborn and immature liver  cells. The fetal liver cells are not fully developed (differentiated) and  secrete a large amount of alpha fetoprotein, which can enter the  maternal blood through umbilical cord blood. Therefore, pregnant  women will test positive for alpha fetoprotein during pregnancy. In clinical practice, AFP is mainly used as a blood marker for primary  liver cancer, for the diagnosis and efficacy monitoring of primary liver  cancer.